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Abstract
In cell and molecular biology, metabolism is the only system that can be
fully simulated at genome scale. Metabolic systems biology offers powerful ab-
straction tools to simulate all known metabolic reactions in a cell, therefore
providing a snapshot that is close to its observable phenotype.
In this review, we cover the 15 years of human metabolic modelling. We
show that, although the past five years have not experienced large improvements
in the size of the gene and metabolite sets in human metabolic models, their
accuracy is rapidly increasing. We also describe how condition-, tissue- and
patient-specific metabolic models shed light on cell-specific changes occurring in
the metabolic network, therefore predicting biomarkers of disease metabolism.
We finally discuss current challenges and future promising directions for this
research field, including machine/deep learning and precision medicine.
In the omics era, profiling patients and biological processes from a multi-
omic point of view is becoming more common and less expensive. Starting
from multi-omic data collected from patients and N-of-1 trials where individual
patients constitute different case-studies, methods for model-building and data
integration are being used to generate patient-specific models. Coupled with
state-of-the-art machine learning methods, this will allow characterizing each
patient’s disease phenotype and delivering precision medicine solutions, there-
fore leading to preventative medicine, reduced treatment, and in silico clinical
trials.
Keywords: Human metabolism, Genome-scale metabolic models, Flux
balance analysis, Metabolomics, Multi-omics
1. Introduction
With the advent of bioinformatics and computational biology, computational
and mathematical techniques can provide accurate simulation of biological pro-
cesses. The most widely used approaches to analyze omics data mainly focus
on genomics, transcriptomics and proteomics, through differential expression
or network-based co-expression analysis. However, genes and their expression
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alone do not always constitute a reliable indicator of cellular phenotype. When
characterizing a phenotypic outcome, relying solely on gene or protein expres-
sion profiles will miss the highly nonlinear interaction between these biological
layers. Such approaches often overlook the metabolic level – the dense network
of biochemical reactions occurring in a cell with the aim of converting nutrients
into energy and cellular building blocks.
Being the best-characterized network in biological systems, and also the
closest to the phenotype, metabolism is arguably the best indicator for the cell
physiological state [1]. Once considered only a passive result of the state of a
cell, it is now widely recognized as a main contributor to cellular behavior. More
specifically, it is a key player in a number of diseases, including diabetes, neu-
rodegenerative diseases, and cancer, where altered metabolism is now accepted
as a hallmark [2].
The recent availability of high-throughput data regarding multiple layers of
biological organization (omics) allows mapping cellular processes at the levels
of genes, mRNA, proteins, and metabolites (Figure 1). In a single experiment,
these measurements are often at both the “genotype” level (i.e., referring to
the genetic elements on a genome) and at the “phenotype” level (the form
and function of the cell). A fundamental question in systems biology is the
definition and understanding of the genotype-phenotype relationship [3]. A
mechanistic link between genotype and phenotype is offered by genome-scale
metabolic models, which contain all known biochemical reactions occurring in a
cell. Such models have been generated taking into account decades of studies in
biochemistry, and in most cases are able to predict the cellular phenotype with
high accuracy.
Constraint-based modelling is the most widely-used approach to model the
behavior of metabolism, often assuming that cells have to fulfill a given task
(e.g. ATP production, growth or proliferation) or to optimize the production
of a given compound. Such models have two main advantages: first, they do
not need dynamic or kinetic data as they are based on mass balance across the
metabolic network; second, they are suitable for integration of different omic
layers at genome scale to improve their predictive performance. In particu-
lar, multi-omic “vertical” integration methods have been proposed to include
omic layers (mainly transcriptomics and proteomics) [4, 5, 6]. Conversely, “hor-
izontal” integration methods have focused on modelling different environments,
cancers or growth conditions starting from the same model [7, 8, 9, 10, 11]. Such
multi-omic integration in genome-scale models has provided a mechanistic link
between the genotype and their phenotypic observables [12, 13, 14, 15]. This
is a key added feature that such models possess if compared with genome-wide
association studies (GWAS), which are able to associate gene variations to phe-
notypic traits, but not to provide a mechanistic explanation of the associations
observed [16].
In this review, we focus on metabolic systems biology, and in particular on
human metabolic modelling. Originally tested and validated with microorgan-
isms, metabolic systems biology is now becoming widespread for human tissues
and biomedical applications [17]. We provide a comprehensive review of the
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Figure 1: The observable phenotype of a cell is a result of complex interactions
and feedback loops among several omic layers, each influenced by environmen-
tal perturbations. In order of “distance” from the cell phenotype, these are epigenomics
(epigenetic markers that affect gene activity and expression), genomics (DNA containing the
genetic code of the cell), transcriptomics (the RNA encoded by the genome), proteomics (the
set of proteins produced as a result of gene expression and subsequent post-translational mod-
ifications), and metabolomics (the set of metabolites and metabolic reactions taking place in
the cell). Although each omic layer can be studied alone, no single omic layer has achieved
a satisfactory correlation with the phenotypic observables. As a result, in recent years, a
multi-omic approach has been adopted where all layers are considered together, and the effect
of interactions and feedback is taken into consideration.
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metabolic models developed so far for human cells, discussing their strengths
and limitations. We show that the main focus of the metabolic modelling com-
munity has shifted from increasing the size of the models - a “size-focused mod-
elathon approach”, often at the expense of reliability of predictions - to team-
based curation approaches where gap filling algorithms and extensive manual
curation improve the reliability of the predictions without necessarily increasing
(and in fact often decreasing) the number of components in the model. We also
outline key success stories, current challenges and future directions for the hu-
man metabolic modelling field, including the integration with machine learning
methods and precision medicine.
2. Metabolic systems biology
Understanding the role of individual components in a biological system is an
important step to elucidate or predict its behavior. However, a major theme in
systems biology is investigating these systems with an integrated approach. In
fact, studying the interactions between different components also gives insights
into the functioning and behavior of the components taken independently [18].
Metabolism is the biggest biological network fully described. It is a surro-
gate of the phenotype, being able to elucidate phenotypic changes caused by
single or combined omics, or physiological factors. It also has the advantage
of being the only system that can be entirely modelled at genome-scale. As
a result, it plays a central role in elucidating the genotype-phenotype relation.
Systems-based approaches have been successfully applied over the last decade
to investigate metabolic networks, composed of a set of chemical reactions and a
pool of metabolites. The first examples of metabolic systems biology appeared
in 1999, and were focused on modelling, connecting and simulating several cel-
lular processes [19]. Whole-cell modelling, named the “grand challenge of the
21st century”, is still an active area of research [20, 21, 22, 23, 24]. In metabolic
systems biology, the value of modelling cell metabolism is not merely explana-
tory of a biological process, but also predictive. A model can be used to suggest
hypotheses that can be tested or to pinpoint unexpected behaviors that can be
further investigated in vitro.
There are different methods to model a metabolic system: steady-state anal-
ysis (e.g. FBA) involves a set of linear equations, while kinetic simulations
involve ordinary differential equations (ODEs). Each variable represents the
variation of a metabolite concentration, in a dynamic or steady state, where the
concentration depends on the rates of the reactions that produce and consume
that metabolite [25]. Kinetic models do not assume steady-state, and therefore
are able to model highly dynamic mechanisms, including allosteric and post-
translational regulation, metabolite concentrations and thermodynamics. Such
ODE-based systems contain a large number of equations (differential or alge-
braic), and require unique kinetic parameter values. They are highly effective
at predicting the behavior of small systems where sufficient experimental data
can be collected for model calibration and parameter estimation [26]. Further-
more, unlike standard FBA-based methods, reaction kinetics can be accounted
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for, and metabolite concentrations can be modelled explicitly, and therefore
intracellular metabolomics data can be integrated directly [27].
For large systems, however, the use of kinetic modelling remains challeng-
ing. The increasing demand for systems-level genome-scale analyses has re-
cently led to the widespread use of constraint-based steady-state models and
their unsteady-state extensions. This has also been facilitated by the increasing
availability of multi-omics data and phenotypic information, used to constrain
the model dynamically and therefore often compensating for the lack of regula-
tory and kinetic modelling.
Following a number of successful attempts at building multi-scale kinetic and
constraint-based models [28, 29], achieving the right combination (and there-
fore trade-off) of kinetic modelling and steady-state assumptions is likely the
next step for the metabolic modelling community. Techniques like unsteady-
state FBA (uFBA) [4] have been recently developed to relax the steady-state
assumption in genome-scale models, with the goal of modelling dynamic cellu-
lar states derived from changes in the concentration of internal metabolites. An
approach to integrate reaction kinetics with steady-state metabolic networks
has also been proposed, where the genome-scale information of shared metabo-
lites among different reactions is used to inform the interactions between the
reactions and predict metabolite concentrations in a network kinetics approach
[30]. More generally, due to the larger range of predictions that kinetic models
can perform compared to steady-state approaches, expanding them towards the
genome scale, or using information derived from genome-scale model simulations
is a promising direction that will increase their spatial and temporal resolution.
2.1. Genome-scale metabolic models
Genome-scale metabolic models contain all known metabolic reactions in
an organism, and can therefore serve as functional databases of cell-specific
metabolism. A genome-scale model is built using the following process. First,
a draft reconstruction is generated starting from the genome and including all
the genome-encoded metabolic reactions. The draft reconstruction also includes
annotated enzyme, reaction and pathway data from databases like KEGG [31],
BioCyc [32], and BRENDA [33]. Details on which genes control each reaction
are also included. Then, a sequence of manual curation steps improves the
draft reconstruction, by gathering evidence to prove or disprove the presence of
a reaction in the network of the organism.
The construction of genome-scale model represents the starting point for flux
balance analysis (FBA, see following subsections). Finally, the model is run and
validated by comparing its predictions with existing experimental results, and
new in silico experiments are performed to further improve and validate the
model. For more details on how to build a metabolic model from the DNA
sequence of an organism, the reader is referred to full protocols [34, 35, 36].
Most genome-scale models are annotated with curated gene-protein-reaction
associations (GPR rules), linking genes with enzymes (Figure 2). Such anno-
tations pave the way for overlaying multi-omic data on the models, using them
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as omic-scaffolds (see Section 2.3). Since omic data can be quantified numeri-
cally and in a condition-, tissue- and patient-specific way (e.g. transcriptomic
profiles, protein levels, metabolite concentrations), models with GPR rules can
serve as a baseline for generating personalized metabolic models. For instance,
personalized predictions using such models can lead to precise phenotypic char-
acterization of patients (see Section 4).
2.2. Constraint-based modelling and flux balance analysis
Flux balance analysis (FBA) is the most widely used constraint-based tech-
nique to predict flux distributions and network capabilities in genome-scale mod-
els [37]. FBA has proved useful thanks to its ability to handle large networks
and predict genome-scale flux distributions. It requires information about bio-
chemical reactions and stoichiometric coefficients, but does not involve kinetic
parameters. This makes it well suited to metabolic engineering studies that
identify and characterize optimal perturbations such as different substrates or
genetic interventions (e.g. knockouts) leading to obligatory coupling between the
growth rate and the overproduction of the desired metabolite [38, 39, 40, 41, 42].
In general, FBA is a powerful tool for predictions of cell behavior under different
metabolic conditions.
FBA is a linear programming technique that models the steady-state condi-
tion in a chemical reaction network [43]. The FBA representation of a genome-
scale model is built based on a stoichiometric matrix S, containing the stoi-
chiometric coefficients of each metabolite (on the rows) in each reaction of the
network (on the columns). A stoichiometric coefficient of a metabolite in a given
reaction is positive if the metabolite is produced by the reaction, and negative
if consumed. An underdetermined linear system of equations Sv = 0 is defined
from the stoichiometric matrix, where the unknows are represented by the vec-
tor v of reaction flux rates. Additional constraints are included as lower and
upper bounds of the fluxes in v (vmin ≤ v ≤ vmax). These account for the
growth or physiological condition, and can be used to incorporate omics data.
One or more cellular objectives (usually growth- or energy-related, e.g. biomass
or ATP), or a linear combination thereof, are finally selected to be maximized
or minimized under the above-mentioned constraints, therefore solving a linear
program.
FBA is therefore based on two main assumptions:
- Homeostatic assumption: the organism has reached a steady state where
the metabolite concentrations are constant and a set of nutrients are being
constantly converted to generate biomass.
- (Multi-level) optimality: in each state, the organism tends to maximize
one or multiple objectives, usually related to growth, biotechnologically-
relevant compound production (e.g. acetate exchange) and important energy-
carrying molecules (e.g. ATP).
FBA is widely used in systems biology to quantify the entire metabolic
steady-state of a cell and calculate its flux distribution. All known metabolic
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Figure 2: The integration of different types of omics data can be used to infer
tissue- and condition-specific intracellular metabolic flux distributions. Intracel-
lular metabolic reactions provide the cell with basic biochemical building blocks, as well as
energy and a thermodynamically favorable environment to sustain its life. Patient-specific
data, molecular information, lifestyle and environmental factors affect different omic levels.
As a consequence, transcriptomic, proteomic and metabolomic data need to be integrated to
determine gene-protein association rules and to build genome-scale models used for personal-
ized predictions. Given the large effect of environmental factors on omics level, determination
of system-level changes in intracellular metabolic fluxes is important for understanding the
fundamental mechanisms of metabolic responses to perturbations. Indeed, environmental
factors affect omics data on different levels, form epigenomics to the cell phenotype. Omic-
augmented genome-scale metabolic reconstructions have proved successful due to the ability
to integrate omic measurements at genome scale and to give mechanistic insights into the
genotype-phenotype relationship.
7
reactions in a given cell are considered, and they are mathematically described in
a way that allows simulation of various states and configurations of the chemical
reaction network. Intuitively, the steady-state constraints used in FBA can be
thought of as Kirchoff’s laws applied to any node representing a metabolite in
the network: the flux through each metabolite in the network must be constant,
namely the input flux must equal the output flux. The combination of steady-
state constraints and capacity constraints on reaction fluxes is a system of linear
homogeneous equations and inequalities; thus, its solution space is a convex
polyhedral cone representing the feasible flux distributions.
The assumptions of FBA and the reduction of the problem to a linear pro-
gram can cause some limitations. First, incorporating or predicting metabolite
concentrations is challenging, and requires a dynamic FBA [44], relaxing the
steady-state [4], flux-sum methods [45], or thermodynamic approaches [46]. Sec-
ond, the reliability of the flux distributions is highly dependent on the objective
function chosen (see Section 2.4), on the quality of the reconstruction and on the
method used to obtain the solution. Regularized FBA methods help alleviate
this issue, as discussed later in this section and in Section 5. Finally, FBA lacks
the ability to directly model regulatory effects or post-transcriptional regulation
of expression levels. Likewise, changes occurring over quick transients (e.g. per-
turbations to the cell microenvironment) cannot be modelled dynamically, but
can be approximated through step-wise before/after simulations [47]. Although
the steady-state rule has been challenged and probabilistic approaches have
been proposed to relax the steady-state equality [48], this assumption enables
the use of linear systems and linear programming, lowering the computational
requirements and enabling fast simulation of genome-scale models in a variety
of growth or physiological conditions.
When solving linear programs for FBA, different solvers can give different
solutions due to numerical implementation differences and to the existence of
multiple alternate optimal solutions [49, 50, 51]. While the value of the objective
function is the same in all the optimal solutions, the other flux rates can vary.
Having a unique solution is therefore important when the full flux distribution
is used for further analysis or as a feature of predictive algorithms. To avoid the
degenerate solutions provided by standard FBA approaches, parsimonious FBA
(pFBA) has been proposed with the aim of minimizing the overall flux carried
by the metabolic network after maximization of the main objective [52]. How-
ever, in some cases, pFBA has produced less plausible results in central carbon
metabolism and in the glycolytic pathway compared to standard FBA methods
[53]. Furthermore, pFBA makes use of the L1-norm (minimization of the sum
of absolute flux values) which does not guarantee a unique solution as it is not
strictly convex [54]. For solving such minimization problems with a guarantee
of a unique solution, the L2-norm should be used instead (minimization of the
sum of squared flux values). Additional approaches to alleviate the problem of
alternate optimal solutions include geometric FBA [55] and sampling [56].
Several tools are available for metabolic model reconstruction, constraint-
based modelling, FBA and related analyses. These include COBRA [57], its
Python version COBRApy [58], RAVEN [59], PathwayTools [60], and FAME
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[61]. For a complete list, the reader is referred to the related reviews and
comparison papers [62, 63].
2.3. Multi-omic flux balance analysis
Although some biological outcomes can be elucidated through single omic
analysis (e.g. protein-protein interaction or gene networks), the vast majority
of phenotypic observables are a result of more comprehensive interconnections
among multiple omics [64]. Regulatory mechanisms also take place at different
omic levels (including transcription, translation and metabolic reactions). The
complex interplay between these levels is responsible for cell behavior. Multi-
omic analyses have been proposed to integrate single-omic networks, based on
co-expression or interaction networks [65]. However, such methods often omit
mechanistic links between omic layers, derived from previous molecular knowl-
edge.
The idea of multi-omic FBA is that by mapping omic data onto in silico
models of metabolism, it is possible to obtain a metabolism-enriched view of
any given omic profile. In this context, as well as permitting the simulation of
large, usually genome-scale, systems in a few seconds of CPU time, FBA also
has the advantage of facilitating the introduction of additional omic layers of
experimental data that can be overlaid onto the model, using GPR rules or
metabolite annotations to place constraints on the flux bounds. Omic-informed
metabolic models consider the mechanistic relation between omics, therefore
correctly representing the prior information available on biochemical networks
[66]. Multi-omic FBA allows assigning the importance of a gene or enzyme
through its predicted function, therefore avoiding approximations or statistical
methods merely based on the value of its expression level.
Following this approach, FBA and its multi-omic modifications have been
used to predict the metabolic response to a given condition in light of the mul-
tiple cellular objectives that a cell is required to meet [67, 68]. Recent studies
have been also aimed at improving the predicting capability of a metabolic
model and elucidating the genotype-phenotype relationship through computa-
tional analyses across multiple omic levels. Predictions of flux distributions after
multi-omic data integration, combined with experimental methods, have been
successfully used to formulate novel biological hypotheses. These techniques
reduce the problem of determining the flux distribution through all reactions
in the system, under a given growth or physiological condition, to a tractable
linear program, under the assumptions of steady-state and optimality. Due to
their scalability and precision, these methods have been used widely, e.g. to pre-
dict bacterial growth phenotypes in specific environmental conditions [69, 70],
to identify novel therapeutic targets against infections [71, 72], to characterize
cancer metabolism of different cell lines [73, 74, 75, 76], and to generate cancer-
vs-normal tissue-specific models for 17 tissues [77]. Further examples of how
this approach has been used to characterize disease metabolism are provided
in Section 4. For a comprehensive review on multi-omic integration techniques
in FBA models, the reader is referred to the recent reviews on omic-informed
metabolic modelling [78, 79, 80, 81].
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Ongoing modelling efforts are aimed at incorporating further biological knowl-
edge in the models. To account for enzyme promiscuity when overexpressing or
underexpressing a gene, GPR rules have been proposed as additional rows of the
stoichiometric matrix, as an enzyme-by-reactions submatrix [53]. For instance,
if multiple reactions are catalyzed by the same promiscuous enzyme, the change
in flux as a result of underexpression/overexpression of the enzyme is distributed
among the reactions (also considering the other enzymes participating in the re-
actions), rather than triggering a priori an equivalent flux increase/decrease in
all the reactions. Codon usage can also be integrated through the GPR rules
[71]. Splice isoform annotations, initially lost and then simply ignored in human
reconstructions, have also received recent attention [82, 83].
Soft constraints can be used to integrate omics data in a reaction-specific
fashion, rather than with a single mathematical rule modifying the constraints
for all the reactions [84]. Further constraints have been also added to integrate
transcriptional regulatory models and metabolic models. The idea is that a
constraint models the correlation between the expression level of a target gene
and that of its regulating genes [6]. To further analyze the reaction flux distri-
butions predicted by multi-omic FBA, sensitivity analysis can be carried out on
genes, reactions or pathways. Definitions of sensitivity scores have been based
on effects of gene knockouts [85], real-valued gene perturbations [69], or the role
of each metabolite in reducing thermodynamic uncertainty in the model [86].
2.4. Choosing an objective function and accounting for multiple cellular goals
The selection of an appropriate objective function is still a challenge in
metabolic modelling. While models of microorganisms can assume that the
cell aims at maximizing growth rate, human cells might not necessarily aim for
maximum biomass (although this is widely accepted as an objective for can-
cer cells). Furthermore, it is now evident that the cellular goal can change
between different cells in a tissue, between tissues, and also over time for the
same cell. For tissue-specific studies, starting from a generic human metabolic
reconstruction (Recon) and using the general-purpose biomass composition of
generic human models can prove unreliable. Recent studies are therefore moving
towards a cell-specific estimation of the biomass compositions [13, 87]. Algo-
rithms for generating and standardizing the biomass reaction [88, 89], and for
automatically generating an objective function have also been proposed [90].
A common assumption in systems biology is that cells tend to optimize
their metabolic network in order to maximize the growth rate (biomass). This
is however still a matter of debate [91], both in terms of its composition [92]
and because in many cases the best objective for a cell is not growth-related
[93]. There is increasing evidence that cells have to cope with multiple, usually
competing, objectives to optimize simultaneously [94]. A single FBA objective
function is not able to capture all of them. It is also likely that metabolism is
not fully optimized for any particular objective [95], and evolution has shaped
cells in order to reach an optimal trade-off between all objectives [96].
Especially in the context of human metabolism, the question ‘what does a
particular cell do?’ has often more than one correct answer. Optimization
10
processes have been proposed that take into account multiple objectives (e.g.
protein or energy production, detoxification, proliferation) with the advantage
of ensuring metabolic flexibility for possible reorganizations performed during
adaptations to changes in the environmental conditions [97]. These methods
include a probabilistic approach [98], lexicographic ordering [99], and the re-
duction to a single objective through the definition of weights for the objectives
[100, 101]. Approaches based on these ideas are fast and can generate a Pareto
front; however, they miss suboptimal solutions, solutions in non-convex regions
[102, 103], or they give preference to one objective [104], therefore addressing
a multi-level problem rather than a strictly multi-objective problem. Although
slower, methods based on evolutionary algorithms are able to explore non-convex
trade-offs without requiring the combination of the objectives into a single ob-
jective function [105, 106, 107]. Exploring a set of trade-off solutions between
competing objectives, rather than a single biomass-maximizing solution, also
accounts for suboptimal solutions [108].
3. 15 years of human metabolic modelling
The study of human metabolism is becoming increasingly important for
biomedical applications as an approach for understanding many diseases and
aspects of health [109, 110]. A systems-level understanding of metabolic behav-
ior is enabled by the availability of high-quality genome-scale reconstructions
integrating extensive metabolic information from various resources. The first
genome-scale metabolic reconstruction efforts focused on bacteria (Haemophilus
influenzae [111], followed by Escherichia coli [112]), due to their simplicity, the
available genome sequences, and the well-known mechanisms of substrate uti-
lization. Reconstructions of human metabolism, which required a much larger
number of pathways and a larger pool of essential nutrients, were attempted at
a later stage, after the publication of the draft and complete human genome
sequences in 2001 and 2004 [113, 114].
HumanCyc [115] (in 2004) and Reactome knowledgebase [116, 117] (in 2005)
were the first successful attempts to build a curated collection of biochemical
reactions in human cells. The first models of human metabolism published in
2007 – Recon 1 [118] and EHMN (Edinburgh human metabolic network recon-
struction, and its subsequent compartmentalized version in 2010) [119, 120] –
achieved a better coverage of the human metabolic network, especially in com-
partments other than the cytosol. Recon 1 contains approximately 1.4 times
more unique metabolites and 2.2 times more reactions than HumanCyc.
In 2013, a large improvement of the number of metabolic processes covered
in the reconstruction was achieved with Recon 2 [121]. This is a consensus
model that includes all reactions from EHMN, Recon 1, HepatoNet1 [122], and
a module for acylcarnitine and fatty-acid oxidation [123]. Compared to Recon
1, Recon 2 represents a major improvement with approximately 1.7 times more
unique metabolites and 2 times more reactions. Recon 2 was then refined in
2015 with updated gene-reaction associations. Simultaneously, a larger recon-
struction named HMR (Human Metabolic Reaction database) [73] was built
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independently, based on HepatoNet1, Recon1, EHMN, Reactome, HumanCyc,
KEGG [31], and the Human Metabolic Atlas [124]. HMR was then extended in
2014 to include lipid metabolism, therefore generating HMR2 [125].
Although containing a large set of reactions and being a consensus model, the
predictions from Recon 2 were incorrect in some cases, mainly due to a number
of incorrectly balanced reactions. At this point, the main focus of the commu-
nity shifted to curation of existing models. Between 2014 and 2015, a series of
minor updates and corrections were published for Recon 2 [126, 127, 128, 129].
In 2016, Swainston et al. performed an extensive curation effort on Recon 2
and its updates, resulting in Recon 2.2 [130]. For the first time, a significant
improvement of an existing model contained fewer genes than the original. In
fact, due to the removal of duplicates and pseudogenes, and to the new unique
HGNC ID convention, Recon 2.2 contains 112 enzyme-encoding genes less than
Recon 2, and for the first time with unified identifiers (grouping splice isoforms
into a single gene). Recon 2.2 is a major improvement for the energy-related
metabolism, with a new compartment simulating the mitochondrial intramem-
brane space. As a result, the ATP and biomass flux predictions were greatly
improved, achieving for the first time accurate predictions of maximum ATP
yield under 14 carbon sources, both in aerobic and anaerobic conditions, and
under 20 additional amino acid carbon sources in aerobic conditions [130].
In 2017, a new human metabolic model named iHsa [131] was obtained as an
expansion and manual curation of HMR2. iHsa is a result of a reconciliation with
the rat metabolic model iRno, also presented in the same paper. Both models
were generated in parallel; rat-specific reactions, thermodynamically infeasible
reaction loops, and other incorrect reactions present in HMR2 and Recon 2 were
removed from iHsa, while new reactions were added from KEGG and Meta-
Cyc/BioCyc [132]. For the first time, rat-specific reactions were removed from
a human metabolic reconstruction. In fact, both models were reconciled and
manually curated focusing on species-specific metabolic differences. The clear
definition of differences between the two metabolic networks, coupled with the
presence of unique reactions in both models opens opportunities for human/rat
cross-species comparison.
In 2018, Recon 3D [133] was developed from Recon 2 by incorporating HMR2
and a number of additional reaction sets, including reactions modelling host-
microbe interaction, reactions for simulating drug effects on human metabolism,
reactions for absorption of dietary compounds, reactions of lipid metabolism
and reactions from metabolomics datasets. 3D protein structures, pharmacoge-
nomics data and atom-atom mappings were also included in the model. After
extensive manual curation steps and refinement of GPR rules, the model was
tested for consistency when replicating 431 essential functions of the human
body. To date, Recon 3D is the largest metabolic reconstruction available for
human metabolism, containing 1.1 times more unique metabolites and 1.4 times
more reactions than Recon 2.
Figure 3 summarizes the progress made by the metabolic modelling com-
munity over the last 15 years. The number of genes, metabolites and reactions
is reported in the figure. To better quantify the connectedness of a model, we
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Figure 3: (Top, left) Number of genes, metabolites, reactions and GPR rules in
human metabolic models. The number of genes in the table refers to the number of
transcripts in the model. (Number of enzyme-encoding genes: Recon 1: 1490, Recon 2: 1789,
Recon 2.2: 1675.) Recon 2 was considered in its latest Recon 2.04 iteration. The GPR rules in
HMR have been extracted as all the non-empty “listOfModifiers” fields via a Matlab custom
script. The boundary metabolites were excluded from the comparison, therefore metabolite
counts represent the size of the stoichiometric matrix on which the model is built. (Bottom,
right) Gene essentiality in the five most recent metabolic models. A gene is deemed
essential if, when knocked out, it induces a biomass value lower than 10−10 h−1. A gene is non-
negligible if, when knocked out, it affects the biomass by more than 10−10 h−1. Although the
improvement in the number of genes and metabolites has been limited in the past five years,
the curation and gap filling efforts have produced more reliable models. As a result, compared
to Recon 2, there has been a sharp increase in the percentage of genes whose knockout yields
measurable effects on the predicted biomass.
computed the number of genes whose knockout yields measurable effects in the
model as measured by the predicted biomass flux. To account for the tolerance
of the linear solver, we defined a gene essential if its knockout produces biomass
< 10−10 h−1; we defined a gene non-negligible if its knockout causes a biomass
variation > 10−10 h−1. Compared to Recon 2, the increase in the number of
genes whose variation has a non-negligible effect on the growth rate shows that
efforts have been successfully made towards curation, gap filling and consistency
checks, as detailed in Section 3.1.
3.1. From size-focused “modelathons” to manual curation
When the first Recon 1 [118] and EHMN [119] human metabolic reconstruc-
tions were published in 2007, Recon 1 was preferred in many studies because
it contained more reactions. In fact, this was only due to the compartmental-
ization of Recon 1, with metabolites repeated in different compartments and
transport reactions between compartments. The number of unique reactions
was indeed greater in EHMN (1028 more reactions and 1202 more metabolites),
and a subsequent compartmentalized version of EHMN was generated [120].
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These frequent comparisons among different models indicate that the main
focus was initially to include as many reactions as possible - a size-focused
“modelathon” approach - often at the expenses of curation and accuracy. Con-
versely, the approach of including all the available biological components in a
model is now always coupled with extensive team-based curation, consistency
checks, uniformity of annotations and gap filling. It is not uncommon to achieve
a better model by removing reactions from an existing one. This encouraged
the community to focus on the accuracy of the models and solvers used, rather
than only on the model size.
Manual curation is therefore considered one of the main steps in generat-
ing a metabolic model. Tools like MetaNetX [134] simplify curation efforts and
suggest identifier mappings to unify reactions and metabolites identifiers. Such
curation efforts are likely to become even more important in the near future
given the recent advances of automated reconstruction tools, now able to gen-
erate a full working draft of a model, e.g. MicrobesFlux [135], Pathway Tools
[136], PathwayBooster [137], CoReCo [138], Merlin [139]. Given the impor-
tance of obtaining reconciled and high-quality models, MetaNetX also provides
a database of models generated after reconciliation of metabolites and biochem-
ical reactions [134]. More recently, CarveMe [140] and RAVEN 2.0 [59] have
shown high potential in automating manual steps, achieving for the first time
an accuracy directly comparable with manually curated models when predict-
ing experimental phenotypes. Tools for checking inconsistencies and for visually
inspecting the model are also available [141].
Over the last few years, the curation efforts have yielded a reduction in the
number of unbalanced reactions, as well as in the number of blocked reactions
and dead-end metabolites. For instance, Recon 2.2 has no unbalanced reactions
apart from the biomass objective functions, and Recon 3 has now less than 15
blocked reactions and dead-ends. Furthermore, as generating context-specific
models using omics relies on GPR rules, the accuracy of these models strictly
depends on the accuracy of the GPR in the baseline model. As shown in Figure
3, GPR coverage is increasing. Finally, the agreement between theoretical and
model-predicted ATP yields has been improved in the most recent models. We
calculated the root mean squared error (RMSE) between the theoretical and
model-predicted maximum ATP yields per unit of carbon source, which has
been reduced from ∞ (Recon 2 and earlier models) to 5.17 (in Recon 3) and
1.67 (in Recon 2.2). The table of ATP yields and the RMSE calculations are
provided as Supplementary Material.
4. Tissue- and patient-specific insights into human disease metabolism
Starting from human generic metabolic reconstructions, a number of success-
ful efforts have been published on reconstructing tissue-specific models. These
include brain [142], adipocytes [143], breast cancer [144], heart [145], kidney
[146], myocytes [147], hepatocytes [125, 148]. A further set of 32 tissue- and
organ-specific models has been generated by mapping protein expression onto
the generic human model HMR2 [125].
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Tissue-specific models are usually built as a reduction of a generic human
model. The reactions that are removed in the construction of the tissue-specific
model are found to be not active in that tissue. Reactions are removed accord-
ing to transcriptomic or proteomic data collected in that tissue, and therefore
the tissue-specific model contains fewer reactions than the generic one. Un-
surprisingly, in most cases they outperform the generic counterpart where they
stemmed from. At this point, a new tissue-specific biomass equation needs
to be established, or the model needs to be set so that the cell can find al-
ternative pathways to sustain its life. Although many methods for generating
tissue-specific models set the goal of creating the minimal metabolic model
that satisfies viability or a set of metabolic tasks, the use of non-minimalistic
methods for generating tissue-specific models should be preferred. For instance,
considering essentiality before removing reactions from a generic model yields a
non-minimal tissue-specific model, but improves model functionality and agree-
ment with experimental data [149]. Since the generic models are a superset of
the tissue-specific models, predictions of generic models may still be correct in
tissue-specific problems, but less accurate.
Context-specific human metabolic models have shed light on disease onset
and progression in a range of recent case studies. In this context, the renewed in-
terest in disease metabolism is due to the fact that a holistic genome-scale view,
rather than a single-gene approach, is necessary to fully characterize most dis-
eases. For instance, in cancer, the differences in the metabolic pathways between
cancer cells and their parent tissue have been characterized using omics data
and a human metabolic model [150, 151, 75]. As a result, tissue- and cell-specific
metabolic models have been successfully used to identify - and successively val-
idate - specific drug targets that inhibit cancer proliferation but do not affect
normal cell proliferation [74, 152]. With a similar approach, submodels built
from human genome-scale models have been used to generate several testable
hypotheses, e.g. to compare wild-type and Fh1-deficient kidney mouse cells, and
to predict further gene knockouts that affect growth in the Fh1-deficient cells
but do not affect the wild-type cells, therefore suggesting targets for treating
hereditary leiomyomatosis and renal-cell cancer [153].
For specific diseases, tissue-specific models have been used successfully to
identify biomarkers and therapeutic targets [125]. Using RNA-Seq expression
levels in combination with genome-scale models has enabled the reconstruc-
tion of cancer cell line-specific models, enabling the discovery of metabolites
supporting proliferation, and antimetabolites1 leading to cell death [154]. Af-
ter integration with extracellular metabolomic data and transcriptomic profiles,
metabolic modelling has reliably characterized intracellular metabolism of lym-
phoblastic leukemia cell lines [155]. A combination of different omics data and
1An antimetabolite is a compound that simultaneously inhibits those enzymes involved
in metabolizing the associated endogenous metabolite. Antimetabolites can affect multiple
enzymes at the same time and can reduce proliferation, and are therefore used as anticancer
drugs.
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flux splits have been used to generate cancer-specific models of the NCI60 panel,
achieving correlation close to 1 in predicting the remaining flux rates [13].
Following the same direction, personalized models (e.g. using patients’ omic
data to constrain the generic reconstruction) hold promise to become key for
precision medicine (Figure 2). The largest study to date with patient-specific
models is the Human Pathology Atlas [77]. The authors built personalized
genome-scale models of cancer in each patient across 17 tissues. This allowed
investigating the metabolic differences between different cancers, as well as
patient-specific biological functions. In another recent study [156], 86 patients
with nonalcoholic fatty liver disease were recruited, and their personalized hep-
atocyte genome-scale metabolic models were built using patient-specific exper-
imental data on lipoprotein fluxes. A new molecular mechanism of the disease
was elucidated as a result of personalized metabolic modelling.
Genotyping coupled with patient-specific metabolic modelling offers a new
opportunity for personalized medicine. In fact, new biomarkers can be pre-
dicted in a patient-specific fashion, and personalized therapies can therefore
be designed and subsequently assessed in terms of their metabolic mechanistic
effects [157]. As shown in a recent case of arginase deficiency (a urea cycle
disorder), different individuals can respond differently to the same disease and
treatment, and this can often be flagged observing their individual metabolic
response [158].
Due to the importance of the gut microbiome composition in human health, a
set of modelling approaches has been proposed recently [159]. Using hostmicro-
biome modelling, e.g. combining metabolic community modelling with human
metabolic models, the interplay among the gut bacteria and their interaction
with the surrounding human cells can be investigated [160, 161]. Personalized
models of gut microbiome have been built from patient-specific metagenomic
data in order to elucidate individual-specific bile acid production in microbiomes
of healthy individuals and patients with inflammatory bowel disease [162]. Al-
though several modelling challenges remain to be solved [163], an approach
based on metabolic modelling is likely to shed light on the role of human gut
microbial communities in human health, therefore suggesting potential dietary
changes or personalized intervention on gut composition [164, 165].
5. Discussion and perspective
Research in computational biology has led to detailed models for a better
understanding of the individual biological components, but arguably to a less
clear picture of the interactions among the components that result in a given
phenotype [166]. Genome-scale systems biology studies can effectively address
this issue. For instance, in biomedical applications, this holistic view is necessary
to characterize a patient’s disease phenotype and deliver precision medicine [17].
Since metabolic homeostasis and observable phenotype are strictly linked,
metabolism is nowadays considered diagnostic of the phenotype, and therefore
arguably the best indicator of the functional state of a cell. Metabolism can
also be used to prioritize genes and assess their function and the role of gene
16
perturbations (including knockouts). Without such integrated analysis, a gene
may e.g. incorrectly be regarded as important only due to its highly variable
expression value.
Metabolic models are increasingly being used to construct multi-scale, multi-
cellular or multi-tissue models. In 2012, a research effort by Karr et al. [21]
provided the first whole-cell computational model of the life cycle of a small
pathogenic bacterium, Mycoplasma genitalium. The model includes metabolism,
replication of the genome, and cell division. Several metabolic models can be
combined in frameworks to investigate the metabolic exchanges between in-
dividual cells and the emerging community behavior [167], with applications
ranging from microbial communities to host-pathogen interactions and cancer
proliferation [168, 169, 170].
The availability of tissue-specific models has also led to the generation of
multi-tissue metabolic models [171]. Further steps in this direction will soon al-
low studying whole-body metabolism models. The first study towards this goal
used dynamic parsimonious FBA to combine steady-state FBA with differential
equations for the concentration of metabolites in each organ [172]. As a result, a
whole-body and inherently multi-scale model was generated with 14 organs plus
the human serum. More recently, the first whole-body metabolic models were
generated named Harvey and Harvetta, where the metabolic network for ev-
ery organ/tissue was built simultaneously from Recon3D [173]. Manufacturing
organ-on-a-chip and ultimately body-on-a-chip devices with metabolic models
(see e.g. [174]) seems the next step in this direction.
Given the recently renewed interest of the scientific community in under-
standing disease metabolism, it is highly likely that cancer metabolism (and
metabolism in other diseases) will become the main research topic in drug devel-
opment. This will complement rather than replace standard transcriptomic-only
studies, and will provide a proxy for the phenotypic and observable outcome.
The idea is that to improve phenotypic predictions, the signatures need to be
taken from sources of data that are closer to the phenotype. The integration
of omics data into metabolic models has enabled the prediction and succes-
sively the validation of biomarkers and therapeutic targets. In drug design,
although genomics, transcriptomics and proteomics are often deemed sufficient,
metabolomics can elucidate mechanisms that are not visible from genes and pro-
tein activity. More importantly, it can address cases where the genes responsible
for a disease are well known but not druggable, but their corresponding down-
stream reactions are [175].
Genomics analysis is usually able to identify known diseases through gene
mutations. However, it may not be able to flag variants of known diseases, or
identify novel diseases. This can happen, for instance, if (i) a gene mutation is
not flagged as important; (ii) the gene is not screened at all; (iii) the disease is
not a direct effect of a gene perturbation; (iv) individuals respond differently
to the same mutation [158]. Genome-scale models can elucidate mechanistic
modes of drug action, side effects (both off-target drug binding and downstream
transcriptional effects), and potential toxicity of drugs by linking omics data to
the phenotype through a condition-specific model [176, 8]. In a patient-specific
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framework, such biological data and markers can be predicted in a personalized
fashion, paving the way for in silico clinical trials [177].
The efforts of the metabolic modelling community are far from being com-
plete. In this regard, we envisage a joint effort from metabolic modelling
and genome-wide association studies (GWAS) communities to identify gene-
metabolite interactions that are currently not included in metabolic models us-
ing state-of-the-art association mappings [178]. Computational tools combining
both approaches would go towards genome-scale detection of errors and missing
enzymatic reactions, remarkably improving the predictive ability of metabolic
models. For instance, this could be achieved by minimizing the error between
predictions of flux coupling and experimental co-expression data integrated with
GWAS [179, 180].
Likewise, the methods for integration of omics data in genome-scale models
still show room for improvement. For instance, in yeast and Escherichia coli,
single-omic integration in FBA has been reported to give similar accuracy to
pFBA without omic integration [78]. Reassuringly, reaction-specific rules to
constrain flux rates can halve the normalized error of pFBA [84]. In multicellu-
lar organisms, a better correlation between gene expression and metabolic fluxes
can be expected [78]. In mammalian cells, the main contributors to the overall
protein expression level are mRNA levels [181, 182], while in most normal and
cancer cell lines, mRNA and protein levels were found to correlate positively
[183, 184]. While different methods (and their parameters) can yield different
context-specific models, the accuracy in predicting essential genes is almost al-
ways higher in context-specific models than in the generic human models [81].
Therefore, metabolic models can be regarded as useful tools to mechanistically
link transcriptomic data with flux rates. Using multiple omics data and thermo-
dynamic constraints simultaneously [185, 186], or a combination of regularized
FBA methods and omics data, can improve the reliability of the predictions
[187].
Compared to the well-characterized microbial metabolic reconstructions,
gaps still present in our knowledge of human metabolism – including char-
acterization of enzymes, the definition of cell-specific metabolic functions and
tissue-specific growth mechanisms – make it more difficult to test (and compare)
metabolic models and omic integration methods. Human metabolic models and
methods have been tested and cross-compared for gene essentiality through
CRISPR-Cas9-mediated loss-of-function screens, and for their ability to pre-
dict growth rate and recapitulate known metabolic functions [81]. A dataset
including both omics data and measured metabolic information is the NCI-60
panel, with metabolite uptake and secretion rates published in 2012 [188]. While
E. coli and yeast fluxomic data is publicly available from several experiments
[189, 190, 191], to the best of our knowledge NCI-60 is the only publicly avail-
able human-cell dataset containing expression levels, metabolic flux rates and
proliferation rates, and therefore suitable for validating FBA methods. Due
to the lack of fluxomic datasets, the difficulty in choosing a reliable objective
function, and the larger size compared to bacterial models, further experimental
validation is needed for human metabolic models, especially when using the full
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flux distribution to inform decisions or subsequent algorithmic steps.
Finally, despite many recent advances, gathering insights from the data gen-
erated through omic-informed models remains a bottleneck in systems biology.
We therefore envisage that genome-scale metabolic models will be increasingly
investigated with machine/deep learning algorithms in a patient-specific fashion
[192, 13]. In disease modelling, the usefulness of general biomarker discovery
is debatable when information on patients is not taken into account, because
most biological components would be flagged as perturbed in a general “disease
versus normal” analysis. Conversely, if the appropriate person-specific data is
integrated with a model, biomarkers can become the central part of precision
medicine, where data acquired on patients drive predictions, analysis and thera-
peutics [17]. In a modelling analogy, machine learning algorithms alone cannot
provide mechanistic information in the biological processes they simulate or
mimic. However, if machine learning is coupled with multi-omic genome-scale
modelling, the combination of experimentally- and model-generated omic data
can predict – and explain mechanistically – personalized therapy predictions by
including key biological information in the learning process.
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